Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction—DAPA-STEMI Trial

Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction—DAPA-STEMI Trial

<b>Background:</b> Myocardial fibrosis leads to ventricular dysfunction and worsened prognosis, especially after ST-segment elevation myocardial infarction (STEMI). Sodium–glucose cotransporter 2 inhibitors (SGLT2is) offer cardiovascular benefits by reducing markers of myocardial fibrosi...

Full description

Saved in:
Bibliographic Details
Main Authors: Luis Ortega-Paz, Claudio Laudani, Alessandro Sionis, Pablo Vidal-Cales, Victor Arevalos, Rut Andrea, Carlos Igor Morr, Oriol De Diego, Emilio Ortega, Francisco-Rafael Jimenez-Trinidad, Ana Paula Dantas, Dominick J. Angiolillo, Manel Sabaté, Jose T. Ortiz-Pérez, Salvatore Brugaletta
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Journal of Cardiovascular Development and Disease
Subjects:
dapagliflozin
myocardial fibrosis
ventricular function
left
myocardial infarction
sodium–glucose transporter 2 inhibitors
Online Access:https://www.mdpi.com/2308-3425/12/6/220
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2308-3425/12/6/220

Similar Items